Sun Pharmaceutical Industries has entered a partnership with AstraZeneca to sell the latter’s Type 2 diabetes (T2D) medicine, dapagliflozin, in India.
Both firms have signed a distribution agreement.
Go deeper with GlobalData
Dapagliflozin tablets are approved as a once-daily oral medication in adult patients with T2D mellitus to improve glycaemic control.
Under the terms, Sun Pharma will promote and distribute dapagliflozin under the brand name Oxra in the Indian pharmaceutical market.
AstraZeneca India will continue to market dapagliflozin under the brand name Forxiga. It will also retain the intellectual property rights to dapagliflozin.
Sun Pharmaceutical India CEO Abhay Gandhi said: “The addition of this innovative Type 2 diabetes treatment bolsters our diabetes portfolio.
“We believe the extended portfolio will further enhance our service capabilities to offer customers and patients innovative medicines at affordable prices.”
Sun Pharma’s current diabetes portfolio includes more than 40 specialty products with a market share of more than 8%.
Following regulatory approval, Sun Pharma will also secure the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name Oxramet.
AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin.
T2D is a chronic syndrome that is caused due to dysregulation of blood sugar levels.
AstraZeneca offers a non-insulin portfolio to treat T2D, which includes dipeptidyl peptidase-4 (DPP-4) inhibitors, SGLT2 inhibitor and glucagon-like peptide 1 (GLP-1) agonists, in India.
Image: Sun Pharma’s global presence is supported by 49 manufacturing facilities across six continents. Photo: courtesy of Sun Pharmaceutical Industries.
